Pharsight

Acetadote patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8399445 CUMBERLAND PHARMS Acetylcysteine composition and uses thereof
Aug, 2025

(1 year, 10 months from now)

US8653061 CUMBERLAND PHARMS Acetylcysteine composition and uses thereof
Aug, 2025

(1 year, 10 months from now)

US8148356 CUMBERLAND PHARMS Acetylcysteine composition and uses therefor
May, 2026

(2 years from now)

US9327028 CUMBERLAND PHARMS Acetylcysteine compositions and methods of use thereof
Jul, 2031

(7 years from now)

US8722738 CUMBERLAND PHARMS Acetycysteine compositions and methods of use thereof
Apr, 2032

(8 years from now)

Acetadote is owned by Cumberland Pharms.

Acetadote contains Acetylcysteine.

Acetadote has a total of 5 drug patents out of which 0 drug patents have expired.

Acetadote was authorised for market use on 23 January, 2004.

Acetadote is available in injectable;intravenous dosage forms.

Acetadote can be used as composition and method for providing a reduction in side effects for human patients in need of acetylcysteine therapy, method of treating acetaminophen overdose with acetylcysteine solutions.

The generics of Acetadote are possible to be released after 06 April, 2032.

Drugs and Companies using ACETYLCYSTEINE ingredient

Market Authorisation Date: 23 January, 2004

Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions; Composition and method for providing a reduction in side effects for human patients in need of acetylcysteine therapy

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of ACETADOTE before it's drug patent expiration?
More Information on Dosage

ACETADOTE family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic